NCT05640804 - A Bioequivalence Study of Dasatinib Tablet | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2018

Primary Completion Date

October 3, 2018

Study Completion Date

October 8, 2019

Conditions

Leukemia, Myelogenous, Chronic

Interventions

DRUG

CTTQ Dasatinib tablet

Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.

DRUG

Sprycel Dasatinib tablet

Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.

Trial Locations (1)

Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun